Benzinga | Mar 1, 2021 05:10AM EST

Grifols Announced it Closed Transaction to Acquire 25 Plasma Donation Centers the U.S. from BPL Plasma, Inc for $370M

Grifols (NASDAQ:GRFS) informs that it has closed the transaction to acquire 25 U.S. based plasma donation centers from BPL Plasma, Inc, a subsidiary of Bio Products Laboratory Holdings Limited, for a total purchase price of USD 370 million. The 25 centers acquired are authorized by the U.S. Food and Drug Administration (FDA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) and during last year collected approximately one million liters of plasma. Grifols will have immediate access to the plasma obtained from these centers.The transaction has received the applicable regulatory clearances, and will be financed from Grifols' own resources.

In 2021, Grifols is ready for a rebound in its plasma-collection levels in the wake of wider vaccination deployments and the ease of COVID-19 constraints. Grifols is also advancing on the execution of its expansion plan, comprising organic and inorganic growth. As part of its organic efforts, the company plans to open between 15 and 20 new plasma centers in 2021.

This acquisition is aligned with Grifols' global expansion and plasma-supply diversification strategy, with 344 plasma centers worldwide: 289 in the U.S. following this transaction and 55 in Europe across Germany, Austria and, recently Hungary. Likewise, Grifols remains committed to increasing its supply of plasma and plasma-derived therapies to ensure patients continue to receive the treatments and healthcare they need.